Ocugen

Yahoo Finance • 2 months ago

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF, is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks... Full story

Yahoo Finance • 10 months ago

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • 10 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccin... Full story

Yahoo Finance • 10 months ago

Q3 2023 Ocugen Inc Earnings Call

Participants Tiffany Hamilton; Head, Corporate Communications; Ocugen, Inc. Shankar Musunuri; Chairman of the Board, CEO & Co-founder; Ocugen, Inc. Michael Breininger; Corporate Controller; Ocugen, Inc. Arun Upadhyay; Chief Scientific... Full story

Yahoo Finance • 10 months ago

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a p... Full story

Yahoo Finance • 10 months ago

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • 11 months ago

Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • 11 months ago

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routes OCU500 will be tested as both inhaled and intranasal vaccine candidat... Full story

Yahoo Finance • 12 months ago

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • 12 months ago

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • 12 months ago

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

FavorablesafetyandtolerabilityprofileofOCU400investigational drug productin RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (ML... Full story

Yahoo Finance • last year

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

MALVERN, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease • OCU400 Clinical Study Results Update... Full story

Yahoo Finance • last year

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story

Yahoo Finance • last year

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Received O... Full story

Yahoo Finance • last year

Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines,... Full story